Concizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors

FRIDAY, Sept. 1, 2023 (HealthDay News) -- Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine.
Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. As part of the explorer7 phase 3 trial, participants were randomly assigned to receive no prophylaxis for at least 24 weeks (group 1; 19 patients) or to receive concizumab prophylaxis for at least 32 weeks (group 2; 33 patients), or they were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4; 81 patients).
The researchers found that the estimated mean annualized bleeding rate in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (rate ratio, 0.14; P < 0.001). For patients receiving concizumab (groups 2, 3, and 4), the overall median annualized bleeding rate was zero episodes. After concizumab therapy was restarted, no thromboembolic events were reported. Plasma concentrations of concizumab were stable over time.
“Concizumab represents a novel, subcutaneous treatment option in patients with hemophilia A or B with inhibitors that can potentially improve long-term outcomes,” the authors write.
The study was funded by Novo Nordisk.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Un pequeño estudio apunta a que una pastilla para dormir podría ayudar a prevenir el Alzheimer
VIERNES, 21 de abril de 2023 (HealthDay News) -- Tomar un somnífero en...
FDA Panel Recommends Approval of First RSV Vaccine Given in Pregnancy to Protect Infants
THURSDAY, May 18, 2023 (HealthDay News) -- A panel of advisers to the U.S. Food...
Stay Safe When Winter Storms Cut Your Power
FRIDAY, Jan. 28, 2022 (HealthDay News) -- With a major winter storm bearing...
Almost 20 Million Older Americans Live With Sight-Robbing Macular Degeneration
FRIDAY, Nov. 4, 2022 (HealthDay News) -- In a finding that suggests more...
